Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Todd Neale

August 07, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

Shelley Wood

June 28, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

News Daily News

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

Michael O'Riordan

June 14, 2016

News Daily News

FDA Panel Overwhelmingly Supports Absorb Bioresorbable Stent

Michael O'Riordan

March 16, 2016

News Daily News

FDA Review of Absorb Bioresorbable Stent Does Not Tip Hand Ahead of Tomorrow’s Advisory Panel Meeting

Michael O'Riordan

March 14, 2016

News Daily News

Increased Risk of Device Thrombosis With Bioresorbable Scaffold, but Some Say Risks Can Be Mitigated

Michael O'Riordan

February 23, 2016

News Daily News

FDA Advisory Panel Gives Nod to Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

L.A. McKeown

June 17, 2014

News Daily News

Un Panel Asesor de la FDA Aprueba un Balón recubierto de Paclitaxel para el Manejo de la Enfermedad Femoropoplítea

L.A. McKeown

June 17, 2014

News Daily News

First DES for Above-the-Knee Vascular Disease on the Horizon

L.A. McKeown

October 18, 2011

Advertisement

Top Endovascular News of 2023

Roughly 80% of ESC Guideline Writers Have Financial COIs

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

TCTMD’s Top 10 Most Popular Stories for June 2019

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

FDA Panel Overwhelmingly Supports Absorb Bioresorbable Stent

FDA Review of Absorb Bioresorbable Stent Does Not Tip Hand Ahead of Tomorrow’s Advisory Panel Meeting

Increased Risk of Device Thrombosis With Bioresorbable Scaffold, but Some Say Risks Can Be Mitigated

FDA Advisory Panel Gives Nod to Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Un Panel Asesor de la FDA Aprueba un Balón recubierto de Paclitaxel para el Manejo de la Enfermedad Femoropoplítea

First DES for Above-the-Knee Vascular Disease on the Horizon

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content